British pharma major GSK (LSE: GSK) outperformed expectations with its annual financial results statement, reporting sales of £29.3 billion ($36.1 billion) for the year, an increase of 19%, driven by revenues of £7.4 billion in the final quarter.
The adjusted earnings per share (EPS) result came in at 25.8 pence for the quarter and £1.39 for the full year, taking into account a decline in growth from COVID-19 solutions of around 4%.
The positive outcome was propelled by strong sales of the firm’s blockbuster shingles vaccine Shingrix (recombinant zoster vaccine), leading overall performance in the vaccines division to reach £7.9 billion, a 17% increase.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze